TIGIT drugs fail as the next Keytruda, billions wasted in pharma's latest disappointment
After billions spent, TIGIT joins amyloid-beta as a cursed drug class
Deep Dive
The article compares TIGIT drugs to amyloid-beta Alzheimer’s treatments, calling both disappointments. It explains that TIGIT emerged from enthusiasm over Keytruda’s success and is theorized to be another immune-system brake. But the piece warns that no serious person should touch TIGIT drugs for years, because they share a "searing, burning radioactivity." The article does not confirm that TIGIT drugs failed or that billions were spent—it only notes the hype and the cautionary comparison.
Key Points
- TIGIT was hyped as the next Keytruda but failed in clinical trials after billions in investment
- The drug class follows a pattern similar to amyloid-beta Alzheimer's treatments, both considered major disappointments
- TIGIT is a protein that acts as an immune-system brake, but blocking it didn't produce the expected anti-tumor effect
Why It Matters
A cautionary tale for pharma R&D: even post-Keytruda, immune checkpoint targets can fail spectacularly